Dr. Mehmet Oz on Drug Prices | CMS Medicare Strategy Explained

Drug Pricing and the Most-Favored-Nation Policy

Drug prices in the United States recorded a 3.1% year-over-year decline in July 2026, marking a significant shift in healthcare costs for consumers. Dr. Mehmet Oz, Administrator of the Centers for Medicare and Medicaid Services, stated during an interview on Face the Nation that this decrease is the fastest observed in 63 years. The administration credits this trend to the implementation of the Most-Favored-Nation drug pricing model. Under this program, pharmaceutical companies are required to align their U.S. pricing with the lower rates they charge in international markets, effectively ending what officials call global freeloading. Seventeen major companies, representing 85% of the pharmaceutical sector, have signed on to these terms.

Market response to these changes has been positive, with drug manufacturer valuations increasing due to the newfound stability in the regulatory environment. Dr. Oz emphasized that these negotiations do not dictate prices through government force, but instead link domestic pricing to international benchmarks. This strategy aims to curb the practice where American patients often pay significantly more for identical medications than residents of Europe or Asia. The administration plans to codify this pricing structure through the proposed Great American Health Act, ensuring that all new drugs released by these large entities follow the same international parity rules.

Medicare Solvency and Fraud Reduction Initiatives

The financial stability of the Medicare trust fund remains a primary concern, as trustees project potential insolvency within six to seven years. If this threshold is reached, payment levels face an automatic reduction of 11% according to the Committee for a Responsible Budget. Dr. Oz reported that the administration has initiated an aggressive campaign to address waste, fraud, and abuse to extend the fund's life. In the past year alone, the agency documented $42 billion in savings by identifying and blocking fraudulent claims before payments were processed. A nationwide moratorium on specific durable medical equipment claims has also contributed to these results.

Technological integration is another key component of the agency's strategy to manage costs and improve efficiency. Amy Gleason leads a health tech initiative within the agency that has successfully recruited 800 companies into a participation pledge. This program focuses on data accessibility, increasing the percentage of Americans with easy access to their own medical records from 5% last year to over 50% today. Dr. Oz stated that this move reduces bureaucratic load for doctors, as 50% of providers now use artificial intelligence tools to handle paperwork and provide patient advice. The administration maintains that patients should own their medical data as they are the primary payers for these health services.

Vaccine Policy and Parental Autonomy

Recent data from the Centers for Disease Control and Prevention indicates that 92% of kindergarteners were vaccinated for measles during the last school year. This figure sits below the 95% threshold typically cited for herd immunity. Public health discussions have been complicated by remarks from President Trump regarding the MMR vaccine, where he suggested that receiving three vaccinations at separate times might be safer than combined doses. Merck, the primary manufacturer of the MMR vaccine, has noted that it does not currently offer the components as separate shots and maintains that such a production shift is not feasible within a ten-year timeframe.

Dr. Oz defended the administration's stance on vaccine autonomy during the interview, arguing that parents should retain the right to ask questions and determine the timing of pediatric vaccinations. He noted that while the federal government pays for these programs, the states retain authority over mandates. The administration advocates for expanded exemptions for religious or personal beliefs, suggesting that a one-size-fits-all schedule is not ideal. Critics point out that separating vaccinations or delaying them can increase costs and leave children vulnerable to diseases like hepatitis B, which infants may encounter through household exposure. The current administration maintains that providing parents with choices is a priority, even as public health experts express concern over the potential impact on overall vaccination rates.